Double-digit sales growth in its Definity and TechneLite contrast agent product lines boosted Lantheus Medical Imaging parent company Lantheus Holdings to an 11.2% increase in worldwide revenues in its third quarter.
For the period (end-September 30), Lantheus had revenues of $88.9 million, compared with $79.9 million in the third quarter of 2017. The company had net income of $9.3 million, up from $8.5 million in the same period a year ago.
Lantheus reaffirmed its 2018 worldwide revenue guidance range of $337 million to $342 million. It also increased its full-year guidance range for adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to $90 million to $93 million, up from previous guidance of $85 million to $90 million.
